Advertisement
BIVI vs RARE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIVI is a StrongBuy and RARE is a StrongBuy.
BIVI in upward trend: price may jump up because it broke its lower Bollinger Band on October 13, 2026
BIVI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 38 cases where BIVI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BIVI's RSI Oscillator exited the oversold zone, 26 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 57 cases where BIVI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on BIVI as a result. In 64 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for BIVI just turned positive on October 21, 2026. Looking at past instances where BIVI's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
Following a +3.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIVI advanced for three days, in 194 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
BIVI moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BIVI crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BIVI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.063) is normal, around the industry mean (2.973). P/E Ratio (-0.420) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. BIVI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for RARE turns positive, indicating new upward trend
RARE saw its Momentum Indicator move above the 0 level on October 19, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 73 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RARE's RSI Indicator exited the oversold zone, 26 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for RARE just turned positive on September 22, 2026. Looking at past instances where RARE's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Following a +10.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where RARE advanced for three days, in 220 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 152 of 226 cases where RARE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
RARE broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.404) is normal, around the industry mean (2.973). P/E Ratio (-2.736) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.809) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. RARE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BIVI | RARE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 17 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 79 | 64 | |
P/E GROWTH RATING 1..100 | 29 | 11 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RARE's Valuation (17) in the Biotechnology industry is somewhat better than the same rating for BIVI (57) in the null industry. This means that RARE’s stock grew somewhat faster than BIVI’s over the last 12 months.
RARE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIVI (100) in the null industry. This means that RARE’s stock grew similarly to BIVI’s over the last 12 months.
BIVI's SMR Rating (99) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that BIVI’s stock grew similarly to RARE’s over the last 12 months.
RARE's Price Growth Rating (64) in the Biotechnology industry is in the same range as BIVI (79) in the null industry. This means that RARE’s stock grew similarly to BIVI’s over the last 12 months.
RARE's P/E Growth Rating (11) in the Biotechnology industry is in the same range as BIVI (29) in the null industry. This means that RARE’s stock grew similarly to BIVI’s over the last 12 months.
| BIVI | RARE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 79% | 2 days ago 72% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 78% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 76% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 72% |
| Advances ODDS (%) | 1 day ago 83% | 3 days ago 79% |
| Declines ODDS (%) | 8 days ago 90% | 9 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 67% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIVI’s FA Score shows that 1 FA rating(s) are green while RARE’s FA Score has 2 green FA rating(s).
- BIVI’s FA Score: 1 green, 4 red.
- RARE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIVI’s TA Score shows that 6 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).
- BIVI’s TA Score: 6 bullish, 4 bearish.
- RARE’s TA Score: 5 bullish, 3 bearish.
Price Growth
BIVI (@Biotechnology) experienced а +13.27% price change this week, while RARE (@Biotechnology) price change was +5.14% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
BIVI is expected to report earnings on Nov 09, 2026.
RARE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement